- November 14, 2016 from 12:00 PM to 1:30 PM
- Presented by: Richard Colonno, PhD, and Qi Huang, PhD, Director of Biology
- Summary: Assembly has developed a proprietary series of CpAM compounds that can both suppress viral replication and inhibit the formation of cccDNA in HBV cell infection assays. In comparison, nucleos(t)ide therapy, such as the the current HBV standard of care drug entecavir, can efficiently block viral replication but has only a modest impact on cccDNA levels.
ContactsInvestors:Assembly Biosciences, Inc.Lauren Glaserlglaser@assemblybio.comMedia:Barbara Lindheimbarbara@assemblybio.com212 584-2276